Featured Publications
Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses
Tsang J, Schwartzberg P, Kotliarov Y, Biancotto A, Xie Z, Germain R, Wang E, Olnes M, Narayanan M, Golding H, Moir S, Dickler H, Perl S, Cheung F, Center T, Consortium T, Obermoser G, Chaussabel D, Palucka K, Chen J, Fuchs J, Ho J, Khurana S, King L, Langweiler M, Liu H, Manischewitz J, Pos Z, Posada J, Schum P, Shi R, Valdez J, Wang W, Zhou H, Kastner D, Marincola F, McCoy J, Trinchieri G, Young N. Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses. Cell 2014, 157: 499-513. PMID: 24725414, PMCID: PMC4139290, DOI: 10.1016/j.cell.2014.03.031.Peer-Reviewed Original ResearchConceptsPre-existing antibody titersPostvaccination antibody responsePeripheral blood mononuclear cell transcriptomeB cell responsesBaseline time pointPostvaccination responsesInfluenza vaccinationImmune monitoringSerum titersAntibody titersAntibody responseBaseline predictorsBaseline differencesImmune parametersHuman immunityCell responsesSubpopulation frequenciesTime pointsCell populationsIntra-individual variationVaccinationTiters
2024
Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Khurana S, King L, Manischewitz J, Posadas O, Mishra A, Liu D, Beigel J, Rappuoli R, Tsang J, Golding H. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature Medicine 2024, 30: 2771-2776. PMID: 39013430, DOI: 10.1038/s41591-024-03189-y.Peer-Reviewed Original ResearchCross-neutralizing antibodiesH5N1 vaccineNeutralizing antibody responsesVaccination of adultsDevelopment of effective vaccinesGlobal public health threatHPAI H5N1Influenza virusSeroconversion ratesH5N1Neutralizing antibodiesCross-reactive bindingPublic health threatLicensed vaccinesHemagglutination inhibitionPublic health priorityAntibody responseEffective vaccineHPAIVaccineAntibodiesDoseHealth priorityVirusHealth threat
2022
Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses
Hagan T, Gerritsen B, Tomalin LE, Fourati S, Mulè MP, Chawla DG, Rychkov D, Henrich E, Miller HER, Diray-Arce J, Dunn P, Lee A, Levy O, Gottardo R, Sarwal M, Tsang J, Suárez-Fariñas M, Sékaly R, Kleinstein S, Pulendran B. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nature Immunology 2022, 23: 1788-1798. PMID: 36316475, PMCID: PMC9869360, DOI: 10.1038/s41590-022-01328-6.Peer-Reviewed Original ResearchConceptsAntibody responseDay 1Vaccine-induced antibodiesYellow fever vaccineHuman immune responseMechanisms of immunityB cell activationTranscriptional atlasFever vaccineDifferent vaccinesSystems vaccinologyImmune responseMost vaccinesDay 7Cell activationInnate immunityVaccineVaccinationImmunityCommon predictorsMolecular signaturesResponsePlasmablastsInterferonAntibodiesPan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination
Fourati S, Tomalin LE, Mulè MP, Chawla DG, Gerritsen B, Rychkov D, Henrich E, Miller HER, Hagan T, Diray-Arce J, Dunn P, Levy O, Gottardo R, Sarwal M, Tsang J, Suárez-Fariñas M, Pulendran B, Kleinstein S, Sékaly R. Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination. Nature Immunology 2022, 23: 1777-1787. PMID: 36316476, PMCID: PMC9747610, DOI: 10.1038/s41590-022-01329-5.Peer-Reviewed Original ResearchConceptsAntibody responsePro-inflammatory response genesToll-like receptor ligandsBlood transcriptional profilesHigher serum antibodyPro-inflammatory responseSerum antibodiesDifferent vaccinesImmune responseImmune stateMetabolism alterationsEndotypesImmune systemVaccinationReceptor ligandsCell proliferationGene expression characteristicsActivation stateDifferential expressionTranscriptional profilesResponse genesExpression characteristicsResponseWide variationAdjuvantEarly human B cell signatures of the primary antibody response to mRNA vaccination
Kardava L, Rachmaninoff N, Lau W, Buckner C, Trihemasava K, Blazkova J, de Assis F, Wang W, Zhang X, Wang Y, Chiang C, Narpala S, McCormack G, Liu C, Seamon C, Sneller M, O’Connell S, Li Y, McDermott A, Chun T, Fauci A, Tsang J, Moir S. Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2204607119. PMID: 35759653, PMCID: PMC9282446, DOI: 10.1073/pnas.2204607119.Peer-Reviewed Original ResearchConceptsMemory B cellsAntibody responseDose 2MBC populationsB cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Durability of antibodiesSubsequent antibody levelsB cell signaturesIgG antibody responsePrimary antibody responseSyndrome coronavirus 2Weak antibody responseMessenger RNA vaccinesPlasmablast frequencyFirst doseMRNA vaccinationMonth 6Antibody levelsProtective immunitySecond dosesAntibody titersCoronavirus 2
2019
Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation
Austin JW, Buckner CM, Kardava L, Wang W, Zhang X, Melson VA, Swanson RG, Martins AJ, Zhou JQ, Hoehn KB, Fisk JN, Dimopoulos Y, Chassiakos A, O'Dell S, Smelkinson MG, Seamon CA, Kwan RW, Sneller MC, Pittaluga S, Doria-Rose NA, McDermott A, Li Y, Chun TW, Kleinstein SH, Tsang JS, Petrovas C, Moir S. Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. Science Translational Medicine 2019, 11 PMID: 31776286, PMCID: PMC7479651, DOI: 10.1126/scitranslmed.aax0904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, NeutralizingAntibody AffinityAntigens, CD19B-LymphocytesCytokinesFemaleGerminal CenterHIV InfectionsHumansImmunologic MemoryLymph NodesMaleMiddle AgedMutation RatePhenotypeReceptors, Antigen, B-CellT-Box Domain ProteinsT-Lymphocytes, Helper-InducerTranscriptomeYoung AdultConceptsHIV-specific B cellsT-betGC B cellsGerminal centersB cellsLymph nodesPoor affinity maturationChronic immune activationMemory B cell compartmentAntibody-mediated immunityChronic infectious diseaseOptimal antibody responseB cell compartmentChronic human infectionsB cell receptorHIV viremiaImmunologic outcomesHIV infectionViremic individualsChronic viremiaImmune activationPeripheral bloodProtective antibodiesAntibody responseCD19
2018
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
Khurana S, Coyle E, Manischewitz J, King L, Gao J, Germain R, Schwartzberg P, Tsang J, Golding H. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. Npj Vaccines 2018, 3: 40. PMID: 30302282, PMCID: PMC6167326, DOI: 10.1038/s41541-018-0076-2.Peer-Reviewed Original ResearchAntibody responseWhole genome-fragment phage display librariesGenome-fragment phage display librariesNeuraminidase inhibition antibody titersVaccine-induced antibody responsesFragment phage display librariesHeterologous H5N1 strainsPolyclonal antibody responsePandemic influenza strainsAffinity maturationNAI titerUnadjuvanted vaccineAntibody titersNeutralization titersSeasonal strainsVaccine platformImmune responseInfluenza strainsAS03Antibody affinity maturationFuture vaccinesImmune memoryViral hemagglutininEpitope diversityVaccine